Has Adam Bied, MD received payments from drug or device companies?

Yes. Drug and device makers reported $31,258 in general payments to Adam Bied, MD across 302 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Adam Bied, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Adam Bied, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Adam Bied, MD

Addiction Medicine · Reading, MANPI 1104185586

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (53.2%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) accounts for 79.2% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2023 at $13,931 and has fallen 96.1% since, to $546 in 2025. Among addiction medicine clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$31,258in general payments, 2019–2025

Across 302 payments — averaging $103.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$25K
Supernus Pharmaceuticals, Inc.$2K
AbbVie$1K
Ironshore Pharmaceuticals Inc.$950
Otsuka America Pharmaceutical, Inc.$554
Lundbeck LLC$460
plus $1K from 9 others

What the payments were for

Consulting fees$3,10510%
Speaking & faculty fees$16,62053%
Travel & lodging$3,04310%
Food & beverage$8,47727%
Education$140%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	79	$24,761
Supernus Pharmaceuticals, Inc.	70	$1,769
AbbVie	51	$1,384
Ironshore Pharmaceuticals Inc.	26	$950
Otsuka America Pharmaceutical, Inc.	14	$554
Lundbeck LLC	20	$460
Takeda Pharmaceuticals U.S.A., Inc.	15	$299
Neurocrine Biosciences, Inc.	6	$255
Braeburn Inc.	6	$204
Axsome Therapeutics, Inc.	7	$201
Cequr Corporation	1	$136
Gilead	1	$124
Corium, LLC	4	$104
Idorsia Pharmaceuticals US Inc	1	$33
Vertical Pharmaceuticals, LLC	1	$24

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$31,258 in reported general payments places this provider in the 95th percentile of 57 addiction medicine providers in Massachusetts.

See all addiction medicine providers in Massachusetts →

Medicare billing

Part B allowed, 2024

$28,828

Medicare patients

Services billed

249

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Desvenlafaxine Succinate ErDesvenlafaxine Succinate	14	$524
Clozapine	17	$446
Sertraline Hcl	21	$301
Venlafaxine Hcl ErVenlafaxine Hcl	16	$152
Fluoxetine Hcl	17	$73

Paid to pharmacies, not to this prescriber.